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Type 1 Diabetes Mellitus Immunotherapy: 
Using regulatory T cells to balance the immune response 
T1DM:	THE	DISEASE	 REGULATORY	T	CELLS	
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Figure	1:	Schema6cal	representa6on	of	the	current	Treg	immunotherapies	used	in	the	T1DM	treatment.	In	vivo	therapies	are	composed	of	a	mainly	autoan6gen	and	are	formulated	with	diﬀerent	adjuvants,	they	usually	induce	
regulatory	cytokine	produc6on	and	augment	T	reg	numbers.	Ex	vivo	therapies	usually	start	with	an	isolated	T	 	CD4+	CD127+	CD25+	popula6on,	they	will	be	expanded	by	diﬀerent	methods,	and	later	reinfused	into	the	pa6ent.	
They	usually	end	in	an	augment	of	the	C-pep6de,	peripheric	T	reg	numbers	and	less	insulin	need.							Made	with	PowerPoint	
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Type	 1	 Diabetes	 Mellitus	 (T1DM)	 is	 a	 chronic	 autoimmune	 disease	 where	 insulin-
producing	 pancrea6c	 ß	 cells	 are	 eﬃciently	 destroyed	 by	 autoreac6ve	 T	 cells,	 causing	
hypoinsulemia	 and	 therefore	 uncontrolled	 hyperglucemia.	 It	 is	 a	 complex	 disorder	 in	
which	many	other	eﬀectors	are	involved	such	as	macrophages,	NK	cells,	dendri6c	cells	and	
B	cells.		
The	disease	is	divided	in	four	diﬀerent	stages:	
enviromental	(virus,	microbiota,	diet)	and	gene6c	(HLA	class	II	genes	DRB1	
DQB1	DQA1)	factors.	
islet	autoan6bodies	are	created	against	pancrea6c	an6gens	(insulin	B	
chain,	GAD65,	HSP60)	
ß-cell	mass	start	to	be	destroyed	by	autoreac6ve	T	cells.	
severe	disglycemia,	symptoma6c	stage.	
Treg	
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T1DM	is	mainly	a	children	disease:	85%	of	the	cases	à	10-14	years	old	children.	
The	lowest	incidences	are	found	in	China	and	South	America,	and	the		
highest	incidences	in	the	Nordic	countries,		
UK,	Portugal,	Canada	and		
also	New		
Zeland.	
Regulatory	 T	 cells	 belong	 to	 a	 suppressive	 T	 cell	 lineage	 that	 regulate	 T	 cell	 responses,	
establish	 tolerance	 and	 regulate	 the	 eﬀectors	 triggered	 during	 the	 immune	 response	 by	
expressing	inhibitory	cytokines,	cytolisis,	metabolic	disrup6on,	compe66on	or	dendri6c	cell-
targe6ng.	There	are	two	types	of	regulatory	T	cells:	
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There	is	a	clear	rela6onship	between	Treg	cells	and	T1DM,	with	a	func<onal	altera<on	
within	this	popula6on	that	leads	to	the	loss	of	self-tolerance.	The	equilibrium		
between	T	reg	and	T	eﬀ	cells	is	unbalanced		
and	might	be	therefore	a	
causa6ve	
eﬀect. 	 		
	
	
Type	1	Diabetes	Mellitus	(T1DM)	is	a	chronic	autoimmune	disease	aﬀec<ng	millions	of	people	worldwide.	Immunoregula<on	may	be	achieved	in	many	ways,	one	of	the	
most	promising	is	regulatory	T	cell	therapy.	Here	will	be	discussed	the	numerous	T1DM	a_er-diagnosis	therapies	that	are	currently	being	involved	in	clinical	trials	or	
have	proved	to	be	eﬀec<ve	in	animal	models.	
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Since	 the	 Treg	 popula<on	 is	 disbalanced	 in	 T1DM	pa<ents,	 immunotherapies	 increasing	 this	 popula<on	 seem	 the	 ﬁbest	 possibility	 for	 the	 disease	 reversion.	 Among	 all	
therapies	discussed,	only	ex	vivo	T	 reg	expansion	has	presented	remarkable	 results	and	regulatory	T	cells	are	perfectly	on	guard	and	 in	higher	numbers.	The	ﬁnding	of	a	
personalized	treatment	that	could	revert	the	disease	represents	the	main	objec<ve	of	the	diabetes	scien<ﬁc	community.	
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In	vivo	administra6on	of	an	an6gen-based	vaccine	into	the	pa6ent	aiming	to	induce	protec6ve	
immunity	and	produce	an	eﬃcient	T	reg	prolifera6on	that	would	resotre	tolerance.	Based	in	a	
mainly	autoan6gen	involved	in	the	disease	developement.	
Ex	 vivo	 therapies	 are	 based	 on	 an	 isolated	 T	 Reg	 popula6on	 by	 FACS,	 later	 expanded	 by	
diﬀerent	 an6gen-speciﬁc	methods	 and	 then	 reinfused	 again	 into	 the	 pa6ent.	 The	 aim	 is	 to	
obtain	suﬃcient	T	reg	numbers	for	the	disease	regression.	
MODELS	 MODELS	
The	an6gens	used	for	this	therapies	correspond	to	the	ﬁrst	an6gens	against	which	
autoan6bodies	are	created:	
Isola6on	can	be	achieved	eﬃciently	by	FACS	as	described	in	Figure	1.	Several	
methods	have	been	described	to	speciﬁcally	expand	T	reg	cells:	
ü Easy	to	administer	
ü 	Well-studied	
ü 	Global	therapy	
X 	Side	eﬀects	
X 	Aier-diagnosis	 ü 	Less	side	eﬀects	
ü Personalized	
ü 	More	T	reg	numbers	
X 	Therapeu6c	dose?	
X 	Aier-	
			diagnosis	
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Teﬀ:	Eﬀector	T	cells	
Treg:	Regulatory	T	cells	
GadAlum	 Diapep277	
NBI-604	
• GAD65	(Pancrea6c	enzyme	
an6gen)	+	Alum	
• Immunodominant	pep6de	
p277	from	HSP60	(Heat	Shock	
Protein)	
• Altered	pep6de	ligand	of	B9-23	(insulin	
immunodominant	an6gen)	
*	Clinical	trials:	Phase	II	
•  Shii	the	cytokine	enviroment	à	an6-inﬂamatory	
•  Immunomodulatory	cytokines	(IL-5,	IL-10,	TGFß)	
•  Blockade	T	cell	func6on,	prolifera6on	and	diﬀerencia6on	
•  T	reg	induc6on	
•  Less	insulin	need	
•  Disease	regression	
natural	T	Reg	 induced	T	Reg	
•  APC:	ar6ﬁcial/dendri6c	cells	
•  an6C-D3	/	an6-CD28	+	IL-2	
•  HLA	class	II	tetramers	(pep6de-MHC	
complexes)	
•  GILZ-DC	
*	Clinical	trials:	Phase	II	
•  Supress	eﬀector	cell	responses	(infused	cells)	
•  Augment	T	reg	numbers	
•  Augment	C-pep6de	levels	
•  Less	insulin	need	
•  Disease	regression	
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